Clinical Trials Logo

Clinical Trial Summary

The purpose of this neoadjuvant trial is to evaluate efficacy and toxicity of chemotherapy using weekly paclitaxel (arm A) versus the combination of the cdk 4/6 inhibitor palbociclib and standard endocrine treatment (arm B). After 12 weeks treatment is switched crossover. During the 24-weekly treatment period, clinical and radiological evaluations are performed repeatedly. Switch between the treatment arms A and B is allowed in case of lack of response or due to toxicity. A translational subprotocol is a mandatory part of the study protocol, except for use of PET-CT evaluations. Postoperatively, patients receive three 3-weekly courses of chemotherapy with a combination of epirubicin and cyclophosphamide.


Clinical Trial Description

Patients are randomized to either weekly treatment with paclitaxel (arm A) or endocrine treatment in combination with palbociclib (arm B) for 12 weeks. Choice of endocrine treatment is for pre- and perimenopausal women and all men tamoxifen 20 mg daily, alternatively for women in this age cohort, an LHRH analogue in combination with an aromatase inhibitor, for all postmenopausal women treatment with an aromatase inhibitor. The aromatase inhibitors to be used according to local practice are anastrozole 1 mg daily, exemestane 25 mg daily, or letrozole 2.5 mg daily. Pre- or perimenopausal women and all men are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women). Postmenopausal women receive an aromatase inhibitor. After 12 weeks, patients without signs of disease progression (PD) are switched to either endocrine treatment in combination with palbociclib (arm A) or weekly treatment with paclitaxel (arm B) for 12 weeks. Postoperatively, patients receive three 3-weekly courses of chemotherapy with a combination of epirubicin and cyclophosphamide. Before start, after 6, 12, 18 and 24 weeks of treatment, radiological assessments of tumor size are performed using mammography and ultrasound alt. MRI breast; PET-CT, confined to the breast and regional lymph nodes, before start, after 12 and 24 weeks, blood tests before start, after 1 week, 12, 18 and 24 weeks. Physical examinations are performed before start and then four-weekly after weeks 4, 8, 12, 16, 20 and 24 weeks of treatment. In case of disease progression during ongoing study treatment, individualized management in the patient's best interest must be considered, in which case surgery is the primary option. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02603679
Study type Interventional
Source Karolinska University Hospital
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 2015
Completion date December 31, 2031

See also
  Status Clinical Trial Phase
Recruiting NCT04997798 - Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer Phase 2
Active, not recruiting NCT04086875 - A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer N/A
Recruiting NCT04123262 - Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression Phase 2
Completed NCT03870399 - Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression Phase 2
Withdrawn NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Active, not recruiting NCT03503799 - Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer
Recruiting NCT04601116 - The MASTER Study (MAmmary Cancer STatin ER Positive Study) Phase 3
Recruiting NCT05333328 - OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk Phase 4
Terminated NCT01548534 - A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer Phase 3
Completed NCT02997995 - Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure Phase 2
Recruiting NCT05868226 - PRE-I-SPY Phase I/Ib Oncology Platform Program Phase 1
Active, not recruiting NCT01266213 - Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women Phase 2
Completed NCT01439282 - Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer Phase 2
Completed NCT03250676 - Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer Phase 1/Phase 2
Recruiting NCT03750396 - Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer Phase 2
Completed NCT03644186 - To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) Phase 2